US Levodopa prices moved lower through February 2026 as steady export flows and restrained domestic demand outweighed rising logistics costs. Early February saw campaign activity from exporters in India’s Hyderabad cluster and China’s Zhejiang province, keeping cargo volumes available and preventing a supply squeeze. Mid-month, freight inflation punctured landed-cost calculations, but aggressive spot offers from new Indian producers kept seller behavior competitive. Late in the month, U.S. formulators and hospitals drew from existing stocks while prescription volumes held flat, leaving the market broadly stable-to-bearish by month end. Demand from pharmaceutical end-users remained soft across formulators, hospitals and retail chains, with limited forward buying and routine replenishment habits cited by analysts. Extended-release Levodopa formulations gained modest share and provided incremental pull for carbidopa-levodopa tablets and Levodopa API for Parkinson’s treatments, but not enough to offset the broader demand lull. Logistics tightened mid-month as freight activity rose, pressuring importer economics. A near-term rebound is noted, contingent on freight-cost trajectories and domestic demand.
